EQL PHARMA AB (7JK) — Capital Reinvestment Ratio
EQL PHARMA AB (7JK) has a Capital Reinvestment Ratio of 1.03x as of March 2026, meaning it reinvests 1% of its operating cash flow (€16.79 Million) in capital expenditures (€17.22 Million). Check how tangible is EQL PHARMA AB's equity to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
EQL PHARMA AB Capital Reinvestment Ratio (2022–2026)
This chart tracks EQL PHARMA AB's Capital Reinvestment Ratio across 3 annual periods. For the full cash flow conversion analysis, see EQL PHARMA AB (7JK) cash conversion ratio.
Annual Capital Reinvestment Ratio for EQL PHARMA AB (2022–2026)
Year-by-year Capital Reinvestment Ratio for EQL PHARMA AB from 2022 to 2026. See EQL PHARMA AB free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2026 | 2.37x | €28.36 Million | €67.24 Million | ▲ +219.2% |
| 2023 | 0.74x | €27.62 Million | €20.51 Million | ▲ +40.6% |
| 2022 | 0.53x | €41.83 Million | €22.09 Million | — |